Background Sodium glucose co-transporter-2 inhibitors (SGLT2i) such as canagliflozin have been shown to have beneficial ...

The US Food and Drug Administration (FDA) has strengthened its warning for canagliflozin (Invokana, Invokamet, Johnson & Johnson/Janssen) related to the increased risk for bone fractures. The "Adverse ...

The US Food and Drug Administration (FDA) today approved a novel glucose-lowering agent, canagliflozin (Invokana, Janssen Pharmaceuticals) for the treatment of adults with type 2 diabetes.

Interim results from the ongoing CANVAS (Canagliflozin Cardiovascular Assessment Study) clinical trial have found an increased risk of leg and foot amputations associated with the popular diabetes ...

Janssen Research & Development announced results from two Phase 3 clinical studies, DIA3015 and DIA3009, showing that canagliflozin provided substantial and sustained glycemic improvements in adult ...

Presentations at 2 major scientific conferences showed that the SGLT2 inhibitor cut the risk of renal failure or death by 30% and had renal benefits for patients with and without previous ...

Please provide your email address to receive an email when new articles are posted on . Canagliflozin was associated with a 2.1% increase in total iron-binding capacity. Hemoglobin increased by 7.3 ...

Please provide your email address to receive an email when new articles are posted on . The SGLT2 inhibitor canagliflozin improved HF symptoms within 3 months in patients with HF, regardless of ...

Compared to placebo, canagliflozin reduced the risk of the composite primary endpoint (cardiovascular mortality, nonfatal MI, nonfatal stroke) by 14% (HR: 0.86; 95% CI: 0.75-0.97). Compared to placebo ...

Canagliflozin demonstrated cardiorenal benefits to patients with recent and longstanding type 2 diabetes. Canagliflozin treatment affects cardiorenal benefits among individuals with recent and ...

Canagliflozin (Invokana) is now approved for reducing MACE risk in adults with type 2 diabetes and established cardiovascular disease, drug maker Janssen announced Tuesday. The company said the sodium ...